查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790476

美國抗病毒藥物市場規模、佔有率和趨勢分析報告：按類型、藥物類別、分銷管道和細分市場預測，2025-2030 年

U.S. Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Drug Class, By Distribution Channel (Hospital, Retail, Online) And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 60 Pages | 商品交期: 2-10個工作天內

價格

美國抗病毒藥物市場摘要

美國抗病毒藥物市場規模預計在 2024 年為 264.1 億美元，預計在 2030 年將達到 236.1 億美元，2025 年至 2030 年的複合年成長率為 -1%。這一下降主要是由於針對 COVID-19的抗病毒藥物需求下降，以及 2025 年重症患者和相關住院人數大幅下降。

美國抗病毒藥物市場主要驅動力是愛滋病毒、B型肝炎和C肝、皰疹和流感的治療。美國疾病管制與預防中心 (CDC) 估計，美國約有 12 億人感染愛滋病毒，24 億人感染C肝，85 萬人感染B型肝炎。 CDC 的一份報告顯示，截至 2025 年中期，包括流感、新冠肺炎 (COVID-19) 和呼吸道合胞病毒 (RSV) 在內的急性呼吸道疾病在美國仍處於非常低的水平，這減少了對抗病毒藥物的迫切需求。低發病率，加上用於緩解症狀和增強免疫力的補充療法的使用日益增多，正在抑制抗病毒藥物市場的成長。

例如，C型肝炎藥物Sovaldi每片售價約1,000美元，12週治療總費用約8.4萬美元。同樣，Orysio每月售價為2.36萬美元，預計治療時間最長為48週。

美國食品藥物管理局(FDA) 的法律規範在塑造抗病毒產業方面發揮著至關重要的作用。 FDA 嚴格的核准流程確保了其安全性和有效性，近期的核准重點關注聯合治療和兒科適應症。 2025 年 6 月，FDA核准擴大 MAVYRET 的用途，用於治療 3 歲及以上兒童的急性C型肝炎。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗病毒藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國抗病毒藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 美國抗病毒市場：產品線分析

第4章：美國抗病毒藥物市場：按類型估計和趨勢分析

  • 類型細分儀表板
  • 美國抗病毒藥物市場：按類型變化分析
  • 美國抗病毒藥物市場規模及趨勢分析（2018-2030）
  • 品牌
  • 學名藥

第5章美國抗病毒藥物市場：藥物類別估計與趨勢分析

  • 藥品類別細分儀表板
  • 美國抗病毒藥物市場：藥物類別變化分析
  • 美國抗病毒藥物市場規模及趨勢分析（依藥物類別，2018-2030年）
  • DNA聚合酵素抑制劑
  • 逆轉錄酶抑制劑
  • 蛋白酶抑制劑
  • 神經氨酸酶抑制劑
  • 其他

第6章：美國抗病毒藥物市場：應用估計與趨勢分析

  • 應用程式細分儀表板
  • 美國抗病毒藥物市場：應用波動分析
  • 美國抗病毒藥物市場規模及趨勢分析（按應用，2018-2030）
  • HIV
  • 肝炎
  • 皰疹
  • 流感
  • 其他

第7章：美國抗病毒藥物市場：通路評估與趨勢分析

  • 分銷通路細分儀表板
  • 美國抗病毒藥物市場：分銷管道波動分析
  • 美國抗病毒藥物市場規模及趨勢分析（按分銷管道，2018-2030年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • GSK plc.
    • AbbVie, Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Aurobindo Pharma
    • Dr. Reddy's Laboratories Ltd.
    • ADARx Pharmaceuticals Inc.
Product Code: GVR-4-68040-665-5

U.S. Antiviral Drugs Market Summary

The U.S. antiviral drugs market size was estimated at USD 26.41 billion in 2024 and is projected to reach USD 23.61 billion by 2030, growing at a CAGR of -1% from 2025 to 2030. This decline is largely due to the waning demand for COVID-19-specific antivirals, as the number of severe COVID-19 cases and related hospitalizations has dropped significantly in 2025.

Treatments for HIV, hepatitis B and C, herpes, and influenza primarily drive the U.S. market for antiviral drugs. The CDC estimates that about 1.2 billion people in the U.S. are living with HIV, 2.4 billion with hepatitis C, and 850,000 with hepatitis B. The CDC reports that acute respiratory illnesses, including influenza, COVID-19, and RSV, remain at very low levels in the U.S. as of mid-2025, reducing the immediate demand for antiviral medications. This low incidence, combined with the growing use of complementary health approaches for symptom relief and immune support, has moderated the growth of the antiviral drugs market.

Despite these advancements, the high cost of antiviral treatments remains a significant challenge for many patients and healthcare systems in the U.S. For instance, the hepatitis C drug Sovaldi costs approximately USD 1,000 per pill, resulting in a total treatment cost of around USD 84,000 for a 12-week course . Similarly, Olysio's monthly treatment cost is estimated at USD 23,600, with treatment durations extending up to 48 weeks.

Regulatory oversight by the U.S. Food and Drug Administration (FDA) plays an essential role in shaping the antiviral drugs industry. The FDA's rigorous approval process ensures safety and efficacy, with recent approvals emphasizing combination therapies and pediatric indications. In June 2025, the FDA approved the expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

U.S. Antiviral Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global U.S. antiviral drugs industry report based on type, drug class, application, and distribution channel.

  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Branded
  • Generics
  • Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others
  • Application Outlook (Revenue, USD Billion, 2018 - 2030)
  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Drug Class
    • 2.2.3. Application
    • 2.2.4. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antiviral Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Antiviral Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Antiviral Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antiviral Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Antiviral Drugs Market: Type Movement Analysis
  • 4.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Branded
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Generics
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Antiviral Drugs Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Segment Dashboard
  • 5.2. U.S. Antiviral Drugs Market: Drug Class Movement Analysis
  • 5.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
  • 5.4. DNA Polymerase Inhibitors
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Reverse Transcriptase Inhibitors
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Protease Inhibitors
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Neuraminidase Inhibitors
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Antiviral Drugs Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. U.S. Antiviral Drugs Market: Application Movement Analysis
  • 6.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. HIV
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Hepatitis
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Herpes
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Influenza
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Others
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Antiviral Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. U.S. Antiviral Drugs Market: Distribution Channel Movement Analysis
  • 7.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. GSK plc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. AbbVie, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Johnson & Johnson Services, Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bristol-Myers Squibb Company
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Cipla Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Aurobindo Pharma
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Dr. Reddy's Laboratories Ltd.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ADARx Pharmaceuticals Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. Antiviral Drugs Market 2018 - 2030 (USD Billion)
  • Table 3 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Information Procurement
  • Fig. 7 Market Formulation and Validation
  • Fig. 8 Data Validating & Publishing
  • Fig. 9 Market Segmentation & Scope
  • Fig. 10 U.S. Antiviral Drugs Market Snapshot
  • Fig. 11 Type Segment Snapshot
  • Fig. 12 Drug Class Segment Snapshot
  • Fig. 13 Application Segment Snapshot
  • Fig. 14 Distribution Channel Segment Snapshot
  • Fig. 15 Competitive Landscape Snapshot
  • Fig. 16 Parent market outlook
  • Fig. 17 U.S. Antiviral Drugs Market Value, 2024 (USD Billion)
  • Fig. 18 U.S. Antiviral Drugs Market - Value Chain Analysis
  • Fig. 19 U.S. Antiviral Drugs Market - Market Dynamics
  • Fig. 20 U.S. Antiviral Drugs Market - PORTER's Analysis
  • Fig. 21 U.S. Antiviral Drugs Market - PESTEL Analysis
  • Fig. 22 U.S. Antiviral Drugs Market Estimates & Forecasts, By Type: Key Takeaways
  • Fig. 23 U.S. Antiviral Drugs Market Share, By Type, 2024 & 2030
  • Fig. 24 Branded Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Generics Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 U.S. Antiviral Drugs Market Estimates & Forecasts, By Drug Class: Key Takeaways
  • Fig. 27 U.S. Antiviral Drugs Market Share, By Drug Class, 2024 & 2030
  • Fig. 28 DNA Polymerase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Reverse Transcriptase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Protease Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Neuraminidase Inhibitors Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Other Drug Class Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 U.S. Antiviral Drugs Market Estimates & Forecasts, By Application: Key Takeaways
  • Fig. 34 U.S. Antiviral Drugs Market Share, By Application, 2024 & 2030
  • Fig. 35 HIV Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Hepatitis Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Herpes Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Influenza Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Other Applications Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 U.S. Antiviral Drugs Market Estimates & Forecasts, By Distribution Channel: Key Takeaways
  • Fig. 41 U.S. Antiviral Drugs Market Share, By Distribution Channel, 2024 & 2030
  • Fig. 42 Hospital Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Retail Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Online Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Key Company Categorization
  • Fig. 46 Company Market Positioning
  • Fig. 47 Strategy Mapping